2. Academic Validation
  3. Design and synthesis of pyrazole derivatives against neutrophilic inflammation

Design and synthesis of pyrazole derivatives against neutrophilic inflammation

  • Eur J Med Chem. 2023 Oct 26:262:115874. doi: 10.1016/j.ejmech.2023.115874.
Ko-Hua Yu 1,  Kai-Wen Tien 2,  Wei-Chun Wang 1,  Ching-Ho Chi 1,  Keng-Chang Tsai 3,  Chen-Hsi Chou 1,  Tsong-Long Hwang 4,  Hsin-Yi Hung 5
Affiliations

Affiliations

  • 1 School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan.
  • 2 Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan.
  • 3 Ministry of Health and Welfare, National Research Institute of Chinese Medicine, Taipei, 112, Taiwan.
  • 4 Graduate Institute of Natural Products, College of Medicine, Chang Gung University, Taoyuan, 333, Taiwan; Research Center for Chinese Herbal Medicine and Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, 333, Taiwan; Department of Chemical Engineering, Ming Chi University of Technology, New Taipei City, 243, Taiwan; Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, 333, Taiwan. Electronic address: [email protected].
  • 5 School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan, 701, Taiwan. Electronic address: [email protected].
PMID: 37918036 DOI: 10.1016/j.ejmech.2023.115874
Abstract

Neutrophils are the most abundant immune cells. However, neutrophil dysregulation leads to acute and chronic inflammation and is involved in various diseases. The aim of this study was to develop anti-inflammatory agents in human neutrophils. A drug screening was conducted on in-house compounds with the potential to inhibit the respiratory burst, which involves the generation of superoxide anions in human neutrophils. Bioisosteric replacement was then applied to design more active derivatives. The most potent inhibitors of superoxide anion generation activity were compounds 58 and 59, which had IC50 values of 13.30 and 9.06 nM, respectively. The inhibitory effects of 58 and 59 were reversed by H89, a PKA Inhibitor. PDE selective screening indicated that the best inhibitory effects were PDE4B1 and PDE4D2, and the inhibitory activities were 83% and 85%, respectively, at a 10 μM concentration of 59. The final molecular simulation experiment highlighted the slightly different binding poses of 58 and 59 in the PDE4 active site. An in vivo pharmacokinetic study revealed that the half-life of 59 was approximately 79 min when using intravenous bolus administration. This work introduced a new class structure of PDE4 inhibitors resulting in potent neutrophil inactivation activity, with the aim of contributing to new anti-inflammatory drug discovery.

Keywords

Neutrophil; Superoxide anion; YC-1.

Figures
Products